The use of calcium-containing oral phosphate binders, introduced in an effort to avoid aluminum-containing compounds, has led to more frequent episodes of hypercalcemia. This prompted the introduction of continuous ambulatory peritoneal dialysis (CAPD) solutions with diminished calcium content. The problems raised by such solutions included stimulation of parathyroid hormone (PTH) secretion and long-term maintenance of calcium balance. Some of these issues can today be answered on the basis of controlled prospective trials. Variability of the rate of intestinal calcium uptake of bone turnover, of baseline parathyroid activity, and other factors make it necessary to individualize the indication for the use of CAPD solutions with low calcium content.
ScribnerB.H., BuriR., CanerJ.E.Z., HegstromR., BurnellJ.M.The treatment of chronic uremia by means of intermittent dialysis: a preliminary report.Trans Am Soc Artif Intern Organs1960; 6: 114–22.
2.
WingA.J.Optimum calcium concentration of dialysis fluid for maintenance haemodialysis.Br Med J1968; 4: 145–9.
3.
JohnsonW.J.Optimum dialysate calcium concentration during maintenance hemodialysis.Nephron1976; 17: 241–58.
4.
Figures from Annual Report on Management of Renal Failure in Europe, XXIV. XXXIst Congress of the ERA/ EDTA, Vienna, 1994.
5.
NolphK.D.Peritoneal dialysis registry update (Lecture). Syllabus of 14th Annual Conference on Peritoneal Dialysis 1994, Orlando, U. S. A. 1994: 103–29.
MactierR.A., Van StoneJ., CoxA., Van StoneM., TwardowskiZ.Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.Clin Nephrol1987; 28: 222–6.
8.
SlingeneyerA., LarocheB., LoupiE., PetitetA., MionC.Calcium concentration in PD dialysate must be lowered. Exclusive use of CaCO3 as a phosphate binder.Perit Dial Int1992; 12(Suppl 1): 161.
9.
CunninghamJ., SawyerN., AltmannP.Mineral metabolism in CAPD patients treated with CaCO3 and stepwise reduction of dialysate calcium.Kidney Int1990; 37: 455.
10.
Market overview.Fresenius AG, 1994.
11.
Report on Management of Renal Failure in Europe, XXIII, 1992.Nephrol Dial Transplant1994; 9(Suppl 1): 6–26.
12.
WeinreichT., ColombiA., EchterhoffH.H.Transperitoneal calcium mass transfer using dialysate with a low calcium concentration (1. 0 mM).Perit Dial Int1993; 13(Suppl 2): 467–70.
13.
KoppleJ.D., CoburnJ.W.Metabolic studies of low protein diets in uremia. II. Calcium, phosphorus and magnesium.Medicine1973; 52: 597–607.
14.
WeinreichT., RambausekM., RitzE.Is control of secondary hyperparathyroidism optimal with the currently used calcium concentration in the CAPD fluid? (see Comments) Nephrol Dial Transplant1991; 6: 843–5.
15.
HonkanenE., Gronhagen-RiskaC., KalaA-R. CAPD with low-calcium (2. 5 mEq/L) dialysate (LCD) and calcium carbonate.PeritDial Int1992; 12(Suppl 1): 127.
16.
KafkaJ., SpryL.A.Retrospective comparison of patients converted to low Ca++ solution.Perit Dial Int1992; 12(Suppl 1): 130.
17.
MartisL., ZimmermannS.W., DelmezJ.A.Dianeal 2. 5 mEq/L calcium and calcium carbonate in CAPD.Perit Dial Int1992; 12(Suppl 1): 139.
18.
PirainoB., PerlmutterJ.A., HolleyJ.L., JohnstonJ.R., BernardiniJ.The use of dialysate containing 2. 5 mEq/l calcium in peritoneal dialysis patients.Perit Dial Int1992; 12: 75–6.
KawanishiH., TakahashiN., NambaS., ToyotaT., MoriishiM., TsuchiyaT.Clinical effects of low calcium (Ca) CAPD dialysate (Ca: 2. 3 mEq/L) and its problems.Perit Dial Int1992; 12(Suppl 1): 131.
22.
ArgilesA., KerrP.G., CanaudB., FlavierJ.L., MionC.Calcium kinetics and the long-term effects of lowering dialysate calcium concentration.Kidney Int1993; 43: 630–40.
23.
HutchisonA.J., TurnerK., GokalR.Effect of long-term therapy with 1. 25 mmol/l calcium peritoneal dialysis fluid on the incidence of peritonitis in CAPD.Perit Dial Int1992; 12: 321–5.
24.
CunninghamJ., BeerJ., ColdwellR.D., NoonanK., SawyerN., MakinH.L.Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol.Nephrol Dial Transplant1992; 7: 63–8.
25.
WeinreichT., Passlick-DeetjenJ, RitzE.Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group.Am J Kidney Dis1995; 25: 452–60.
26.
TattersallJ.E., DickC., DoyleS., GreenwoodR.N., FarringtonK.Alkalosis and hypomagnesaemia: unwanted effects of a low-calcium CAPD solution.Nephrol Dial Transplant1995; 10: 258–62.
27.
JohnsonD., RigbyR., McIntyreH.A randomized trial comparing 1. 25 mmol/l calcium dialysate to 1. 75 mmol/l calcium dialysate in CAPD patients.Nephrol Dial Transplant1996; (in press).
28.
HutchisonA.J., WhitehouseR.W., BoultonH.F.Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease.Kidney Int1993; 44: 1071–7.
29.
HerczG., PeiY., SherradD.J., ChanW.Aplastic osteodystrophy: effect of lowering dialysate calcium. (Abstract) J Am Soc Nephrol1993; 4: 697.
30.
MalbertiF., ScanzianiR., CorradiB.High-dose oral calcitriol and zero calcium peritoneal solutions in CAPD patients with refractory secondary hyperparathyroidism.Nephrol Dial Transplant1994; 2: 1759–64.
31.
ArmstrongA., CunninghamJ.The treatment of metabolic bone disease in patients on peritoneal dialysis.Kidney Int1994; 48(Suppl 48): 51–7.
